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INTRODUCTION 
 
Subtle clinical presentations of Cushing’s syndrome, characterized by a 
paucity of signs and symptoms due to mild cortisol hypersecretion, are 
increasingly found in clinical practice. In parallel, the metabolic syndrome 
epidemic is leading to a boost in the number of patients with a Cushingoid 
phenotype, who could be potentially candidate to be tested for 
hypercortisolism (1).  
The Endocrine Society guidelines for the diagnosis of Cushing’s syndrome  
recommended against widespread testing for the condition, unless in patients 
with unusual features for age, or multiple and progressive features, 
particularly those that are more predictive of Cushing’s syndrome (2). 
However, unsuspected Cushing’s syndrome was found to be more frequent 
than previously expected in different series of diabetic patients submitted to 
routine screening (3, 4, 5). Thus, a number of patients with Cushing’s 
syndrome may not be recognized while they are managed for diabetes, either 
because of a mild clinical presentation or because of insufficient awareness of 
their physicians. Missing a diagnosis of Cushing’s syndrome may have 
detrimental consequences on patient outcome because hypercortisolism is 
expected to worsen metabolic control and increase the probability of future 
cardiovascular events (6).  
The results of the above-mentioned studies may argue in favor of a 
systematic screening of Cushing’s syndrome in type 2 diabetes. However, 
data were mostly generated in academic centers on hospitalized patients, 
thus raising the possibility of a selection bias toward patients at greater risk 
of Cushing’s syndrome than the general diabetic population (7).  
The aim of our study was to screen patients attending diabetes clinics in an 
outpatient setting and in conditions of standard clinical practice. Cohorts of 
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consecutive patients were enrolled in different Italian diabetes clinics rather 
than selecting groups of patients at higher risk for Cushing’s, i.e. those who 
were hypertensive, overweight, and had poor glycemic control. 
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PATIENTS and METHODS 
Patients 
The study was conducted under the auspices of the Associazione Medici 
Endocrinologi (AME) at 24 diabetes clinics across Italy (Fig/table 1). Written 
informed consent was obtained from all patients, and the institutional review 
board at each center approved the study. Each participating center was 
requested to recruit consecutively at least 20 diabetic patients fulfilling all 
inclusion criteria and without exclusion criteria, who were attending the 
center for an ordinary outpatient visit from June 2006 to April 2008. Follow-
up for this study was closed in September 2010. Patients had to meet the 
following inclusion criteria: age between 18 and 70 years, BMI greater than 
25 kg/m2 and known diagnosis of type 2 diabetes on active follow-up from at 
least 1 year before the study. Exclusion criteria were presence of specific 
Cushingoid features (easy bruising, facial plethora, proximal miopathy and 
striae (2)), any severe acute illness, treatment with drugs known to affect the 
HPA axis or dexamethasone metabolism, current or previous history of 
alcohol abuse or major mood disorders that required psychiatric intervention, 
history of recent surgery or trauma and pregnancy. Any subject with BMI 
greater than 30 kg/m2 was categorized as obese (8). Any subject with 
systolic blood pressure greater than 140 mmHg, diastolic blood pressure 
greater than 90 mmHg, or on antihypertensive treatment was categorized as 
hypertensive (9). Dyslipidemia was defined following the ATP-III criteria: 
total cholesterol >200 mg/dl, high-density lipoprotein cholesterol levels <40 
mg/dl, serum triglyceride levels >150 mg/dl,  low-density lipoprotein 
cholesterol levels >160 mg/dl (10). Patients were also considered 
dyslipidemic if any specific treatment was given. The main characteristics of 
the evaluated patients are shown in Table 1.  
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Materials  and protocols    
All subjects underwent in an outpatient setting a first screening step by 
using the overnight 1-mg dexamethasone suppression test (DST) (1 mg 
dexamethasone administered orally at 2300 h, and blood sample drawing on 
the following morning at 0800 h for determination of serum cortisol 
concentration. Patients who failed to suppress serum cortisol less than 5.0 
g/dl (138 nmol/l) were offered a second-step evaluation by undergoing a 
standard 2-day 2-mg DST, 3–6 months after baseline evaluation (0.5 mg 
dexamethasone administered orally at 06.00, 12.00, 18.00 and 24.00 h, and 
blood sample drawing on the following morning at 0800 h for cortisol 
determination). A cortisol concentration greater than 1.8 g/dl (50 nmol/l) 
was considered abnormal and prompted further evaluation to confirm 
diagnosis of Cushing’s syndrome and determine its cause according to a 
standardized protocol (11). The study flow-chart is outlined in Figure 1. 
Briefly, evaluation included 24-h urine collection for urinary free cortisol 
measurement and blood drawing at 0800 h for determination of plasma 
ACTH concentration. ACTH concentration provided guidance for radiologic 
evaluation (pituitary MRI or adrenal CT); in doubtful cases, the corticotropin-
releasing hormone (CRH) stimulation test was also performed to ascertain 
the ACTH dependency when ACTH concentration was between 10 and 20 
pg/ml (2.2 and 4.4 pmol/l) (12). Specific treatment was pursued in the 
patients with a definitive diagnosis of Cushing’s syndrome who were followed 
up for at least 24 months after surgery. The hormonal variables were 
determined in a single reference laboratory for each participating center 
using commercially available reagents. 
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Statistical analysis 
Sample size analysis was done based on the results of previous studies. It 
was calculated that approximately 381 patients should be studied to provide 
an 80% chance (beta) of detecting a prevalence rate of Cushing’s syndrome 
of 1%, taking 0.05 as the level of significance (alpha). Rates and proportions 
were calculated for categorical data, and means and standard deviations for 
continuous data. Normality of data was assessed by the Kolmogorov-Smirnov 
test. For continuous variables, differences were analyzed by means of the 
two-tailed Student’s t-test when data were normally distributed and by the 
Mann–Whitney U-test for nonparametric data. For categorical variables, 
differences were analyzed by means of the χ2-test and Fisher’s exact test. 
Levels of statistical significance were set at P <0.05. A multiple regression 
analysis was performed when appropriate. All analyses were performed using 
the Statistica® software package (Microsoft Corp, Tucla, OK, USA). 
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RESULTS 
A total of 813 consecutive patients with type 2 diabetes were enrolled. 
They were 428 men (52.6%) and 385 women (47.4%) aged 25–70 years 
(median, 60 years) with a median duration of diabetes of 8 years (range, 1-
20 years). Of the whole cohort, 17.9% of patients were treated with insulin, 
62.2% with oral hypoglycemic agents, 13.7% with a combined therapy, while 
6.2% were on diet alone (patients on glitazones were excluded from the 
study because these drugs reportedly interfere with the HPA axis (13)). 
Overall, 71.7% of patients were hypertensives, 56.5% of whom were treated 
with 2 or more drugs, 58.7% had LDL cholesterol >100 mg/dl, and 79.9% 
were dyslipidemic, 46.8% of whom were on pharmacologic treatment.  
All subjects underwent a first screening step for Cushing’s syndrome using 
the overnight 1-mg DST. In a multiple regression analysis including as 
candidate predictive variables age, BMI, systolic and diastolic blood pressure, 
glycosilated hemoglobin (HbA1c) and fasting glucose levels, post-DST cortisol 
levels were associated with systolic blood pressure (=0.09, P=0.02) and 
HbA1c values (=0.12, P=0.001). However, the model accounted only for 
2% (r2) of the total variation (P=0.007). The patients with HbA1c >7% had 
post-DST cortisol levels higher than the remainders (1.73 ± 2.28 g/dL vs 
1.36 ± 1.23 g/dL, [48 ± 63 nmol/l vs 38 ± 34 nmol/l] p=0.02).  
Forty patients (4.9%) failed to suppress cortisol <5.0 g/dl (138 nmol/l) 
after the 1-mg DST. They were 21 men and 19 women aged 20-70 years 
(median, 56.5 years). The patients failing to suppress cortisol were slightly 
younger with similar duration of disease and BMI compared to the 
remainders. There was no difference in terms of treatment for either 
hypertension or dyslipidemia, while a greater percentage of non-suppressing 
patients was on insulin treatment (51.3% vs 30.4%, p=0.01). Moreover, the 
non-suppressing patients showed greater systolic blood pressure, HbA1c and 
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fasting glucose levels than the patients with post-DST cortisol <5 g/dL (138 
nmol/l) (Table 2).  
The 40 non-suppressing patients underwent a second-step evaluation with 
a standard 2-day 2-mg DST (2). Thirty-four patients (85%) displayed cortisol 
levels <1.8 g/dl (50 nmol/l) and were considered as false-positives after the 
1-mg DST, while the diagnosis of Cushing’s syndrome was confirmed in 6 
patients (0.7% of the whole series) (Table 3). In 5 patients, adrenal-
dependent Cushing’s syndrome was diagnosed on the basis of undetectable 
ACTH concentrations in four of them (cases #1, 2, 3, 5) and undetermined 
ACTH not responsive to the CRH test (basal ACTH 10 pg/ml [2.2 pmol/l], 
peak ACTH 12 pg/ml [2.6 pmol/l] in patient #4). Computerized tomography 
(CT) scan was then performed and an adrenal tumor was found in 4 patients 
(cases #1, 2, 3, 5) while bilateral macronodular adrenal hyperplasia was 
observed in patient #4. The patient with normal ACTH levels (case #6) 
underwent pituitary magnetic resonance imaging (MRI) that did not show any 
lesion and the patient refused further investigation (Table 3). 
Three out of 6 patients with a definitive diagnosis of Cushing’s syndrome 
had less than 50 years (cases #1, 3, 5). Only one patient had HbA1c values 
<7.0% (case #6) and 3 patients had poor glycemic control despite intensive 
treatment (cases #1, 2, 3). Four patients had a difficult to treat hypertension 
(cases #1, 2, 5, 6).  The patients bearing a cortical adenoma underwent 
adrenalectomy and the pathological diagnosis was  adrenal adenoma. Twelve 
months after adrenalectomy, an eucortisolemic state was restored in these 
patients who were able to discontinue all glucose-lowering agents in 3 of 
them (cases #1, 2, 5) and insulin in another (case #2), attaining adequate 
metabolic control; in one patient (case #5) also anti-hypertensive treatment 
could be stopped. The patient with ACTH-independent bilateral macronodular 
hyperplasia (case #4) did not undergo surgery because of poor clinical 
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conditions. 
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DISCUSSION 
Previous studies have shown a prevalence of unsuspected Cushing’s 
syndrome in patients with type 2 diabetes ranging from 0% to 9.4%, even if 
surgical prove was secured in a minority of cases only (Table 4). The studies 
reporting the highest prevalence figures included patients with some features 
conferring an elevated a priori probability of Cushing’s syndrome (such as 
obesity, hypertension and poor diabetes control, which were often 
concomitantly present). Moreover, these studies were done in hospitalized 
patients only. The analysis of the available literature suggests that either the 
study setting (inpatient versus outpatient), the patient characteristics and the 
test cutoff are important factors determining the outcome of the screening 
(Table 4). 
In the present study, we observed a frequency of previously unsuspected 
Cushing’s syndrome of 0.7% in a cohort of 813 patients with type 2 diabetes, 
the largest series up to now reported. Although this figure is low in absolute 
terms to support the efficacy of a widespread screening, it makes Cushing’s 
syndrome much more frequent than previously thought considering that type 
2 diabetes affects about 4% of the adult population in Italy (14). The present 
findings add to previous evidence showing that occult Cushing’s syndrome 
recognizes more frequently an adrenal etiology, whereas overt Cushing’s 
syndrome is more commonly pituitary-dependent (15). These data suggest 
that most cases of Cushing’s syndrome may actually be unrecognized 
because of phenotypic similarities with the metabolic syndrome (1).  
Strengths of our study include the large number of patients, the 
multicentric nature and the outpatient setting of the study, making our 
results generalizable to an unselected patient population. In fact, our patients 
attending the diabetic care units involved in the study are fully representative 
of the general diabetic population in Italy because they present similar 
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demographic, clinical and biochemical features to those reported in the yearly 
surveys on type 2 diabetes in Italy (14). 
The frequency of occult Cushing’s syndrome reported herein was lower 
than in previous studies employing a similar screening strategy (3, 4, 5) and 
this is likely explained by two factors. First, in our study screening was done 
in an unselected population and not only in patients at perceived high risk of 
hypercortisolism. It is pertinent to consider that different procedures of 
screening proved to be ineffective in an outpatient setting, although the 
studies had less statistical power than the present one (16, 17, 18, 19).  
Second, the use of a more specific cutoff point for the 1-mg DST at 5.0 g/dl 
(138 nmol/l). This was deemed appropriate since the study was done in 
conditions of standard clinical practice and not in academic, referral centers. 
Our choice was aimed at limiting additional workload and costs of screening 
to select patients with more than minimal hypercortisolism, likely associated 
with clinical consequences. The entity of hypercortisolism was indeed slight in 
one case only, with a presumably pituitary adenoma.  
In previous studies, the use of cutoff points ranging from 1.8 g/dl (50 
nmol/l) to 2.1 g/dl (58 nmol/l) was associated with a high false-positive rate 
due to the poor specificity of these thresholds (3, 4, 20), whereas a cutoff 
point at 4.0 g/dl (110 nmol/l) provided comparable results (21). Would have 
we used the most sensitive cutoff of 1.8 g/dl (50 nmol/l), as many as 22.6% 
of patients should have been submitted to further testing. This observation 
demonstrates clearly that a screening strategy aimed at maximal sensitivity, 
that should be advocated in principle, is virtually impossible to apply in the 
every-day practice. However, we cannot exclude to have missed a number of 
patients with subclinical Cushing’s syndrome, that is associated with subtler 
alterations of the HPA axis (22). This observation does not limit the clinical 
relevance of our results, since it remains controversial whether subclinical 
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Cushing’s syndrome is associated with long-term morbidity and whether 
treatment to reverse this disorder may be beneficial  (7, 22, 23). 
Two issues are key to the justification of large-scale screening of Cushing’s 
syndrome. First, is occult Cushing’s syndrome associated with a more severe 
metabolic and cardiovascular disease and, second, does its cure have a 
beneficial impact on the outcome of patients? These issues remain mostly 
undefined by the available studies, because of the small number of patients 
who were found to have Cushing and were submitted to specific treatment 
(Table 4). In addition, none of the previous studies reported on long-term 
data after successful treatment of occult Cushing’s syndrome. Discrepant 
results were reported concerning severity of diabetes in occult Cushing (3, 4); 
however, amelioration of diabetes has been reported in the few patients who 
attained remission of hypercortisolism (3, 4, 21).  
In the present study, we observed that the condition of being non-
suppressor to dexamethasone was associated with higher glycemic levels, 
notwithstanding that a greater proportion of such patients were on insulin 
treatment. However, this association seems to reflect a secondary activation 
of the HPA axis in patients with more severe metabolic derangement (24, 
25), since we observed a positive relationship between HbA1c values and 
post-dexamethasone cortisol levels.  
We were able to attain long-term follow-up data of the patients with 
definitive Cushing’s syndrome, thus confirming that surgical cure was 
associated with significant improvement of metabolic control in the 4 patients 
who underwent removal of their adrenal adenoma (Table 3). Diagnosis of 
Cushing’s syndrome was useless in a patient in poor general conditions, who 
is still untreated. Due to the small numbers, we cannot definitively prove that 
screening of Cushing’s syndrome results in a more favorable outcome of the 
patients who were diagnosed with the condition. However, it is noteworthy 
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that all the treated patients were able to discontinue, or reduce, medications 
for diabetes after remission of hypercortisolism.  
In conclusion, the results of the present study do not support the 
application of a wide-scale screening of Cushing’s syndrome in patients with 
type 2 diabetes, unless more efficient screening procedures will become 
available. The frequency of Cushing’s syndrome in an unselected patient 
population was low compared to the number of false positive results to make 
a routine screening strategy applicable in practice.  
Considering the epidemic of type 2 diabetes in the Western World, 
however, the present data suggest that Cushing’s syndrome is less rare than 
previously found (although not frequent enough to warrant systematic 
screening). This is plausible since the available epidemiological data took into 
account only diagnoses made in hospitalized patients, thus considering only 
the most severe and clinically obvious cases (26, 27, 28, 29).  
Our results may influence clinical practice supporting a case-finding 
approach in selected cases. The characteristics of our group of patients with 
a definitive diagnosis of Cushing’s suggest that a difficult control of diabetes 
(and hypertension) despite intensive treatment should prompt screening, 
particularly when features suggestive of hypercortisolism are apparent (1, 2). 
A diagnosis of type 2 diabetes below 50 years of age is another factor that 
should raise suspect, recalling the value of features unusual for age to 
suspect Cushing (2), since the disease usually occurs in older patients (14). 
However, age at diagnosis of type 2 diabetes is shifting among younger 
population (30). The patients found to have occult Cushing’s syndrome 
should be referred to endocrinologists with specific expertise to ensure a 
prompt treatment of the condition that may have a beneficial impact on 
health outcomes. It is pertinent to consider that adrenal adenoma is the 
leading cause of occult Cushing’s syndrome and the fact that laparoscopic 
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adrenalectomy is become a safe and relatively inexpensive procedure, 
causing a limited discomfort to the patient (31), makes more attractive the 
search for the condition.  Since patients with occult Cushing’s syndrome have 
a milder clinical phenotype, physicians involved in management of diabetes 
should raise their level of awareness for the condition. The knowledge and 
experience of the physician is key in this context, thus the present data 
suggest that a specific educational policy may lead to an improved care of 
patients with type 2 diabetes.  
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Table 3  Characteristics of the patients with definitive Cushing’s syndrome.  Ricontrollare l’outcome dei pazienti e dare UFC 
 
# Sex 
Age 
(yrs) 
BMI  
(kg/m2) 
HbA1C  
(%) 
 T2DM 
duration 
(yrs) 
T2DM    
therapy 
HTN 
therapy         
(n° of 
drugs) 
Cortisol 
post DST 
(g/dl) 
Cortisol post 
Liddle I 
(g/dl) 
UFC 
(g/24h) ACTH 
(pg/ml) 
Imaging test 
Tumor 
found       
(size [mm]        
/ side) 
Patient 
outcome 
1 M 32 44.9 11.0 5 
OHA + I 3 
20.8 13.7 
 
<5 Adrenal CT 25/right 
Treatment of T2DM 
stopped after ADX 
2 F 69 57.3 10.6 11 OHA + I 6 12.6 2.1  <5 Adrenal CT 32/right Deceased after xx months 
3 M 20 28.0 12.0 2 
OHA + I 0 
16.5 12.1 
 
<5 Adrenal CT 28/left 
Treatment of T2DM 
stopped after ADX 
4 M 68 32.8 7.8 20 I 2 13.3 2.8  10 Adrenal CT BMAH ?? 
5 M 44 26.7 7.8 4 
OHA  5 
23.3 20.0 
 
<5 Adrenal CT 31/left 
Treatment of T2DM and 
HTN stopped after ADX 
6 F 67 26.0 6.4 1 
OHA 3 
6.2 17.4 
 
22.9 
Pituitary 
Pituitary MRI 
- 
?? 
Abbreviations are as follows: T2DM, type 2 diabetes; HTN, hypertension; DST, dexamethasone suppression test; OHA, oral 
hypoglycemic agents; I, insulin; CT, computerized tomography; ADX, adrenalectomy; BMAH, bilateral macronodular adrenal 
hyperplasia; MRI, magnetic resonance imaging. 
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Figure1  Algorithm of the screening strategy used in 813 patients with type-2 diabetes. 
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Table 1  Main characteristics of the patients. 
Data are expressed as mean values and standard deviations. 
 
Variable  
Age [years] 58.9 ± 8.9 
BMI [kg/m2] 32.1 ± 6.1 
Duration of disease [years] 9.8 ± 7.9 
Fasting glucose [mg/dl] 174.7 ± 67.7 
HbA1C [%] 8.4 ± 1.9 
Systolic blood pressure [mmHg] 138.2 ± 17.2 
Diastolic blood pressure [mmHg] 82.6 ± 10.1 
Total cholesterol [mg/dl] 186.9 ± 48.7 
HDL cholesterol [mg/dl] 45.9 ± 23.7 
LDL cholesterol [mg/dl] 106.9 ± 45.6 
Triglycerides [mg/dl] 171.2 ± 157.2 
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Table 2 Comparison of patients with post-DST cortisol ≤5 g/dl (DST suppressors) 
and post-DST cortisol >5 g/dl (DST non-suppressors). Data are 
expressed as mean values and standard deviations. 
 
 
 DST 
suppressors 
DST                         
non-suppressors 
p 
Age [years] 58.6 ± 8.8 55.5 ± 11.9 0.03 
BMI [kg/m2] 32.1 ± 6.1 31.7 ± 6.4 NS 
Duration of disease [years] 9.8 ± 7.9 8.8 ± 5.7 NS 
Fasting glucose [mg/dl] 172.5 ± 65.1 222.9 ± 100.7 <0.0001 
HbA1C [%] 8.4 ± 1.9 9.3 ± 2.0 0.005 
Systolic blood pressure [mmHg] 137.9 ± 17.2 147.1 ± 16.9 0.02 
Diastolic blood pressure 
[mmHg] 
82.6 ± 10.1 80.7 ± 10.9 NS 
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